Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) shot up 10% during mid-day trading on Friday . The stock traded as high as $14.90 and last traded at $14.74. Approximately 4,624,310 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 8,185,436 shares. The stock had previously closed at $13.40.
Analyst Upgrades and Downgrades
SLS has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Report on SLS
SELLAS Life Sciences Group Stock Up 14.0%
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01).
Hedge Funds Weigh In On SELLAS Life Sciences Group
Several institutional investors and hedge funds have recently bought and sold shares of SLS. Nykredit A S bought a new stake in SELLAS Life Sciences Group during the second quarter valued at about $27,000. Wellington Management Group LLP lifted its position in shares of SELLAS Life Sciences Group by 73.2% during the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after buying an additional 252,531 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at approximately $7,823,000. Dagco Inc. grew its stake in shares of SELLAS Life Sciences Group by 19.8% during the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after acquiring an additional 203,653 shares during the period. Finally, Bank of America Corp DE increased its holdings in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock worth $2,714,000 after acquiring an additional 540,748 shares in the last quarter. 17.38% of the stock is currently owned by hedge funds and other institutional investors.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Featured Stories
- Five stocks we like better than SELLAS Life Sciences Group
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
